Clinical Trial

A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is being conducted to characterize the efficacy and safety of nirogacestat in Japanese adults with progressing desmoid tumors/aggressive fibromatosis.
Protocol Amendment History 6 changes
notable Primary completion pushed: 2027-03-31 -> 2027-05-28 2026-06-30
notable Sponsor changed: SpringWorks Therapeutics, Inc. -> SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany 2026-05-09
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-07
notable Enrollment increased: 18 -> 20 participants 2026-04-07
notable Primary completion moved earlier: 2028-05-31 -> 2027-03-31 2026-04-07
minor Completion moved earlier: 2030-12-31 -> 2029-10-31 2026-04-07
Trial Details
NCT Number NCT07170644
Lead Sponsor SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Conditions Desmoid Tumor, Aggressive Fibromatosis
Enrollment 20 participants
Start Date 2025-08-08
Primary Completion 2027-05-28 (estimated)
Study Completion 2029-10-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-29